tetano
Editor, Senior Moderator
Microorganisms
. 2021 Feb 9;9(2):339.
doi: 10.3390/microorganisms9020339.
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
Arthur Dechaumes[SUP] 1 [/SUP], Magloire Pandoua Nekoua[SUP] 1 [/SUP], Sandrine Belouzard[SUP] 2 [/SUP], Famara Sane[SUP] 1 [/SUP], Ilka Engelmann[SUP] 1 [/SUP], Jean Dubuisson[SUP] 2 [/SUP], Enagnon Kazali Alidjinou[SUP] 1 [/SUP], Didier Hober[SUP] 1 [/SUP]
Affiliations
Abstract
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy. Though the understanding of the disease has improved, fighting the virus remains challenging. One of the strategies is repurposing existing drugs as inhibitors of SARS-CoV-2. Fluoxetine (FLX), a selective serotonin reuptake inhibitor, reportedly inhibits the replication of RNA viruses, especially Coxsackieviruses B (CVB), such as CV-B4 in vitro and in vivo. Therefore, in this study, we investigated the in vitro antiviral activity of FLX against SARS-CoV-2 in a model of acute infection. When 10 μM of FLX was added to SARS-CoV-2-infected Vero E6 cells, the virus-induced cytopathic effect was not observed. In this model, the level of infectious particles in the supernatant was lower than that in controls. The level was below the limit of detection of the assay up to day 3 post-infection when FLX was administered before viral inoculation or simultaneously followed by daily inoculation. In conclusion, FLX can inhibit SARS-CoV-2 in vitro. Further studies are needed to investigate the potential value of FLX to combat SARS-CoV-2 infections, treat SARS-CoV-2-induced diseases, and explain the antiviral mechanism of this molecule to pave way for novel treatment strategies.
Keywords: SARS-CoV-2; coronavirus; fluoxetine; in vitro.
. 2021 Feb 9;9(2):339.
doi: 10.3390/microorganisms9020339.
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
Arthur Dechaumes[SUP] 1 [/SUP], Magloire Pandoua Nekoua[SUP] 1 [/SUP], Sandrine Belouzard[SUP] 2 [/SUP], Famara Sane[SUP] 1 [/SUP], Ilka Engelmann[SUP] 1 [/SUP], Jean Dubuisson[SUP] 2 [/SUP], Enagnon Kazali Alidjinou[SUP] 1 [/SUP], Didier Hober[SUP] 1 [/SUP]
Affiliations
- PMID: 33572117
- DOI: 10.3390/microorganisms9020339
Abstract
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy. Though the understanding of the disease has improved, fighting the virus remains challenging. One of the strategies is repurposing existing drugs as inhibitors of SARS-CoV-2. Fluoxetine (FLX), a selective serotonin reuptake inhibitor, reportedly inhibits the replication of RNA viruses, especially Coxsackieviruses B (CVB), such as CV-B4 in vitro and in vivo. Therefore, in this study, we investigated the in vitro antiviral activity of FLX against SARS-CoV-2 in a model of acute infection. When 10 μM of FLX was added to SARS-CoV-2-infected Vero E6 cells, the virus-induced cytopathic effect was not observed. In this model, the level of infectious particles in the supernatant was lower than that in controls. The level was below the limit of detection of the assay up to day 3 post-infection when FLX was administered before viral inoculation or simultaneously followed by daily inoculation. In conclusion, FLX can inhibit SARS-CoV-2 in vitro. Further studies are needed to investigate the potential value of FLX to combat SARS-CoV-2 infections, treat SARS-CoV-2-induced diseases, and explain the antiviral mechanism of this molecule to pave way for novel treatment strategies.
Keywords: SARS-CoV-2; coronavirus; fluoxetine; in vitro.